Contact
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Siegel TU Braunschweig Universitätsbibliothek Braunschweig
You do not seem to be within the network of Braunschweig University.
As student, researcher or staff member of Braunschweig University you can use the VPN service to gain access to electronic publications.
Alternatively, you can use your university username and password via Shibboleth to gain access to electronic publications with certain publishers. You can find more details in our Blog (in German).

Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment

OBJECTIVEIn inflammatory bowel disease (IBD), hepatic disorders are frequently due to nonalcoholic fatty liver disease and drug-induced hepatotoxicity. Immunosuppressive treatment is known to exert hepatotoxic side effects by a still unknown mode. The relevance of liver steatosis for the development... Full description

Contributors: Schröder, Torsten
Schmidt, Klaus J
Olsen, Vera
Möller, Steffen
Mackenroth, Tilo
Sina, Christian
Lehnert, Hendrik
Fellermann, Klaus
Büning, Jürgen
Contained in: European journal of gastroenterology & hepatology Hagerstown, Md : Lippincott Williams & Wilkins Vol. 27, No. 6 (2015), p. 698-704
Journal Title: European journal of gastroenterology & hepatology
Fulltext access:
Availability is being checked...
Interlibrary loan: Check possibility for interlibrary loan
Links: Volltext (dx.doi.org)
PubMed (www.ncbi.nlm.nih.gov)
ISSN: 0954-691X
DOI: 10.1097/MEG.0000000000000350
Language: English
Notes: Copyright: Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ID (e.g. DOI, URN): 10.1097/MEG.0000000000000350
PPN (Catalogue-ID): OLC1958348775
more publication details ...

Associated Publications/Volumes

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03318naa a2200433 c 4500
001 OLC1958348775
003 DE-601
005 20160618125600.0
008 160206s2015 000 0 eng d
016 7 |a 10342394  |2 DE-600 
024 7 |a 10.1097/MEG.0000000000000350  |2 doi 
028 5 2 |a PQ20160617 
035 |a c1820-54c636263ff67523d4b3a9d8d45ba0a1355437e38d2b5d2d94c4647050f26dd50 
035 |a 0180792720150000027000600698liversteatosisisariskfactorforhepatotoxicityinpati 
040 |b ger  |c GBVCP 
041 0 |a eng 
082 0 9 |a 610 
245 0 0 |a Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment 
500 |a Copyright: Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. 
520 |a OBJECTIVEIn inflammatory bowel disease (IBD), hepatic disorders are frequently due to nonalcoholic fatty liver disease and drug-induced hepatotoxicity. Immunosuppressive treatment is known to exert hepatotoxic side effects by a still unknown mode. The relevance of liver steatosis for the development of drug-related hepatotoxicity in IBD is unknown. METHODSThe charts of 259 patients with IBD under immunosuppression with either azathioprine, 6-mercaptopurine, or methotrexate were reviewed. The prevalence of liver steatosis was assessed by means of ultrasound reports. Aspartate transaminase and alanine transaminase above the normal range were used to indicate liver abnormalities. RESULTSLiver steatosis on the basis of ultrasound criteria was observed in 73 patients (28.2%). In patients with liver steatosis, the presence of elevated liver enzymes (ELE) was found to be significantly more prevalent (28.8 vs. 14.5%, P=0.0095). The finding of liver steatosis was associated with higher age (44.1 vs. 34.5 years, P<0.0001) and body weight (BMI 26.7 vs. 23.4 kg/m, P<0.0001). Development of ELE under immunosuppression was seen in 50 patients (19.3%). Of the patients who developed ELE, 44.0% (vs. 24.4%, P=0.0095) showed liver steatosis. Logistic regression analysis revealed that male individuals showed an increased likelihood of developing ELE associated with steatosis (P=0.0118, odds ratio=3.93) and that patients who received steroids less often developed ELE in association with liver steatosis (P=0.0414, odds ratio=0.31). CONCLUSIONThis study suggests that fatty liver represents a risk factor for hepatotoxicity in patients with IBD under immunosuppressive treatment and should be routinely considered in treatment strategies. 
700 1 |a Schröder, Torsten 
700 1 |a Schmidt, Klaus J 
700 1 |a Olsen, Vera 
700 1 |a Möller, Steffen 
700 1 |a Mackenroth, Tilo 
700 1 |a Sina, Christian 
700 1 |a Lehnert, Hendrik 
700 1 |a Fellermann, Klaus 
700 1 |a Büning, Jürgen 
773 0 8 |i in  |t European journal of gastroenterology & hepatology  |d Hagerstown, Md : Lippincott Williams & Wilkins  |g Vol. 27, No. 6 (2015), p. 698-704  |q 27:6<698-704  |w (DE-601)170274918  |x 0954-691X 
856 4 1 |u http://dx.doi.org/10.1097/MEG.0000000000000350  |3 Volltext 
856 4 2 |u http://www.ncbi.nlm.nih.gov/pubmed/25923946 
901 |a OLC 
912 |a SYSFLAG_A 
912 |a GBV_OLC 
912 |a GBV_ILN_12 
912 |a GBV_ILN_219 
951 |a AR 
952 |d 27  |j 2015  |e 6  |h 698-704